Analyst Ratings For Rocket Pharmaceuticals (NASDAQ:RCKT)
Today, Cowen initiated coverage on Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform.
Some recent analyst ratings include
- 3/9/2018-Cowen initiated coverage with a Outperform rating.
- 1/30/2018-Evercore ISI initiated coverage with a Outperform rating.
- 7/12/2017-Canaccord Genuity was Downgraded by analysts at Canaccord Genuity from a “Buy ” rating to a ” Hold” rating.
- 7/11/2017-HC Wainwright was Downgraded by analysts at HC Wainwright from a “Buy ” rating to a ” Neutral” rating. They now have a $2.00 price target on the stock.
- 1/3/2017-Piper Jaffray Companies was Downgraded by analysts at Piper Jaffray Companies from a “Overweight ” rating to a ” Neutral” rating. They now have a $3.00 price target on the stock.
- 12/1/2016-Roth Capital initiated coverage with a Buy rating.
- On 1/6/2017 David P. Southwell, Insider, bought 60,000 with an average share price of $1.75 per share and the total transaction amounting to $105,000.00.
- On 5/13/2016 J Martin Carroll, Director, bought 10,000 with an average share price of $9.03 per share and the total transaction amounting to $90,300.00.
- On 2/23/2015 Argeris N Karabelas, Director, bought 603,832 with an average share price of $6.00 per share and the total transaction amounting to $3,622,992.00.
- On 2/23/2015 Park Bioventures Lp Devon, Major Shareholder, bought 814,166 with an average share price of $6.00 per share and the total transaction amounting to $4,884,996.00.
Recent Trading Activity for Rocket Pharmaceuticals (NASDAQ:RCKT)
Shares of Rocket Pharmaceuticals closed the previous trading session at 18.15 up +0.18 1.00% with shares trading hands.
